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system, which can lead to disparities in treatment. METHODS:
Using nationally representative data from the Medicare Current
Beneﬁciary Survey, 1992–2003 and the Medical Expenditure
Panel Survey, 1999–2003, we estimated the out-of-pocket prices
for common opioid analgesics among community-dwelling
adults in theUnited States. Standardized gamma mixture models
were estimated to predict out-of-pocket prices for individuals
with and without drug coverage controlling for setting charac-
teristics, such as year, as well as prescription speciﬁc attributes
such as number of tablets and controlled release form.
RESULTS: Typical prescription for opioid analgesics costs a
patient between $6.20 and $64.17, if they have drug coverage,
and between $16.22 and 134.60 without coverage. CONCLU-
SION: A better understanding of the endogeneity of out-of-
pocket prices not only improves our ability to identify the
demand for health care, these models better characterize the
ﬁnancial burden of pain management.
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OBJECTIVES: To identify lower back pain (LBP) patients who
use narcotic medications and examine their medication behav-
iors, medical and pharmacy claim costs and associated comor-
bidities. METHODS: This study used medical and pharmacy
claims data from 165,569 employees’ ages 18 to 64 years from
three employer groups from September 2002 to December 2003.
LBP patients were identiﬁed using ICD-9 diagnosis codes from
medical claims data. Differences in costs and comorbidities were
examined between LBP patients who use narcotic medications
and LBP patients who do not use narcotic medications.
RESULTS: Among eligible members, 13,760 (8.3%) were iden-
tiﬁed as LBP patients. Nearly 60% were female with an average
age of 46.8 years. Approximately half of the LBP patients
(44.8%) used narcotic medications; however, they consumed
71% of total health care costs (medical plus pharmacy costs)
among LBP patients. The average monthly total health care cost
for a narcotic-using LBP patient was $1,040 versus $347 for a
LBP patient without narcotics. Narcotic-using LBP patients had
signiﬁcantly (p < 0.001) higher rates of comorbid conditions than
LBP patients without narcotic use: hypertension (22.9% vs.
13.3%), arthritis (14.1% vs. 4.3%), diabetes (10.4% vs. 5.6%),
asthma (7.4% vs. 4.0%), coronary artery disease (5.0% vs.
2.5%), depression (10.3% vs. 5.4%) and anxiety (6.3% vs.
2.8%). Also, LBP patients with comorbid anxiety or depression
on average used more narcotic medications than patients with
other comorbidities. LBP patients who use narcotic medications
are also more likely to visit the emergency room, use physical
therapy or chiropractic services, utilize one or more epidurals
and/or MRI’s, or have a surgery (p < 0.001). CONCLUSION:
Lower back pain patients who use narcotic medications are more
likely to have additional health conditions and higher health care
costs than non-narcotic using LBP patients. Further, patients
with comorbid anxiety or depression take more narcotics than
those with other comorbidities.
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OBJECTIVES: To estimate the costs of device-related events
associated with intravenous patient-controlled analgesia (IV
PCA) from the perspective of a hospital or integrated health-
system. METHODS: To estimate the costs attributable to both
harmful and non-harmful IV PCA device-related events, a quasi-
cost accounting methodology is utilized. Data were obtained
from the Manufacturer and User facility Device Experience
(MAUDE) dataset, published literature, and expert opinions.
The MAUDE dataset is publicly available, and contains manda-
tory FDA reports of medical device-related events. IV PCA event
reports were identiﬁed from the MAUDE database (January 1,
2002-December 31, 2003) and the descriptive text was qualita-
tively reviewed to collect data on event consequences. The level
of care rendered for the event consequences was estimated by
applying clinical assumptions validated by an expert advisory
panel. Both variable and opportunity costs (2006 values) were
considered, including medication, laboratory, lost revenue, and
labor. Whenever an event consequence was indicated in a report,
the corresponding costs were applied to derive the estimated
mean cost for each event type. The event types were previously
deﬁned and published (Device Safety Events, Operator Errors,
Adverse Reactions to Opioids, Patient-related Events, and Inde-
terminate Events). RESULTS: The most costly event type was
Adverse Reactions to Opioids, followed by Operator Errors
(mean costs of $13,803 and $2,955 respectively). When strati-
ﬁed, events reported to be harmful to patients were associated
with higher costs than non-harmful events: $3483 vs. $0 for
Device Safety Events, $5756 vs. $361 for Operator Errors, $199
vs. $11 for Patient-related Events, and $6120 vs. $142 for Inde-
terminate Events; by deﬁnition, Adverse Reactions to Opioids
were all harmful events. CONCLUSION: IV PCA device-related
events are costly to hospitals due to their association with patient
care consequence. This study provides an innovative approach
to estimating the cost of device-related events. Additional
research is necessary to validate these ﬁndings.
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OBJECTIVES: The objective of this study was to estimate the
frequency and cost of medication errors associated with intra-
venous patient-controlled analgesia (IV PCA) from the perspec-
tive of a hospital or integrated health-system. METHODS: This
study utilized a quasi-cost accounting methodology to estimate
the costs attributable to both harmful and non-harmful IV PCA
errors. Data for the study were obtained from the MEDMARX®
dataset, published literature, and expert opinions. MEDMARX
is an anonymous error-reporting database maintained by the
United States Pharmacopeia. The database accepts multiple
inputs of error causes and error consequences per event (i.e.,
error cause and consequence categories not mutually exclusive).
The level of care rendered was estimated by applying clinical
assumptions (validated by an expert advisory panel) to each 
